Detail akcie UCB SA online

Business Summary: Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, UCB SA revenues decreased 5% to EUR5.25B. Net income before extraordinary items decreased 18% to EUR343M. Revenues reflect Vimpat segment decrease of 65% to EUR394M, Other Products segment decrease of 53% to EUR153M, USA segment decrease of 15% to EUR2.45B, Japan segment decrease of 17% to EUR269M. Net income also reflects Marketing/Selling Expenses increase of 7% to EUR1.59B (expense).